ARS Pharmaceuticals, Inc. (SPRY) Reports Q1 Loss, Lags Revenue Estimates

ARS Pharmaceuticals, Inc. (SPRY) came out with a quarterly loss of $0.35 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.11 per share a year ago. These figures are adjusted for non-recurring items.A quarter ago, it was expected that this company would post a loss of $0.04 per share when it actually produced earnings of $0.52, delivering a surprise of 1,400%.Over the last four quarters, the company has surpassed consensus EPS estimates just once.ARS Pharmaceuticals, Inc., whi ...